Approval · Notice of Compliance 29816 · 2023
RADICAVA: Notice of Compliance 29816
Issued January 4, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29816
- Date
- January 4, 2023
- Company
- Mitsubishi Tanabe Pharma CorporationChuo-Ku, Osaka-Fu, Japan
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Changes to the manufacturing sites of the resins and the compositions of the resins. Changes to the secondary packaging.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RADICAVA | Not yet assigned | — |
Medicinal ingredients
- EDARAVONE 30 MG per 100ML